Time to Symptom and mPAP Improvement with Winrevair
Winrevair (sotatercept) demonstrates significant improvement in exercise capacity by 24 weeks, with the primary endpoint of 6-minute walk distance showing a placebo-adjusted median increase of 41 meters at this timepoint 1.
Timeline of Clinical Improvements
Exercise Capacity (6-Minute Walk Distance)
- Week 24: Primary assessment shows median improvement of 34.4 meters from baseline (placebo-adjusted difference of 40.8 meters) 2
- This represents the definitive timepoint where clinically meaningful improvement is documented in the pivotal STELLAR trial
- The improvement meets the minimally important difference threshold of 33 meters established in PAH literature 3
Hemodynamic Parameters (mPAP and PVR)
While the FDA label focuses on the 24-week primary endpoint for 6MWD, earlier phase 2 data (PULSAR trial) provides insight into hemodynamic changes:
- Week 24: Significant reduction in pulmonary vascular resistance observed, with mean difference of -239.5 dyn·sec·cm⁻⁵ in the 0.7 mg/kg dose group 4
- A recent meta-analysis confirms mean pulmonary artery pressure reduction of -14.94 mmHg at study end 5
WHO Functional Class
- Week 24: 29% of patients improved by at least 1 WHO functional class compared to 14% on placebo 1
Clinical Worsening Events
The reduction in clinical worsening events (84% risk reduction) was assessed over a median duration of 33.6 weeks of exposure, suggesting sustained benefit beyond the 24-week primary endpoint 1.
Important Caveats
Dosing escalation timeline: Sotatercept starts at 0.3 mg/kg and escalates to the target dose of 0.7 mg/kg, administered every 3 weeks 1. This means patients require multiple doses before reaching target dosing, which factors into the timeline for maximal effect.
Background therapy requirement: All patients in STELLAR were on stable background PAH therapy (61% on triple therapy, 35% on double therapy, 40% receiving prostacyclin infusions) 1. The 24-week improvement timeline applies specifically to patients already optimized on background therapy.
Monitoring requirements: Hemoglobin levels must be assessed before at least the first 5 doses and periodically thereafter due to erythrocytosis risk 1, which may influence dose escalation timing and thus time to maximal benefit.
Practical Application
For clinical decision-making, expect to assess meaningful improvement at the 24-week mark (approximately 6 months), which aligns with standard PAH follow-up intervals recommended by guidelines 6. Earlier hemodynamic improvements may occur, but 24 weeks represents the validated timepoint for clinical decision-making based on the pivotal trial design 2.
The ESC/ERS guidelines recommend follow-up assessments every 3-6 months in stable patients 6, making the 24-week assessment point a natural checkpoint for evaluating sotatercept response.